BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

NCT04044001 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Tuberculoses
Other Specified Pulmonary Tuberculosis

Interventions

DRUG: BTZ-043
DRUG: Rifafour e-275®
DRUG: Probe Drug Cocktail
DRUG: Dolutegravir 50mg Tab

Sponsor

Michael Hoelscher

Collaborators

[object Object]
[object Object]
[object Object]